Inactive Instrument

Clarus Therapeutics Holdings, Inc.

CRXT

US18271L1070

First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.

December 28, 2022 at 11:00 pm EST

Clarus Therapeutics Holdings, Inc. filed a motion in the US Bankruptcy Court seeking the extension of its exclusivity periods on December 29, 2022. As per the motion, the debtor seeks to extend its exclusivity periods for both, to file a plan and to solicit votes on a plan, by 60 days i.e. up to March 6, 2023 and May 4, 2023, respectively.

Latest news about Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. Went Out of Business	23-02-28	CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.	23-02-09	CI
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.	23-01-16	CI
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.	22-12-28	CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.	22-12-22	CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	22-12-21	CI
Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	22-12-01	CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer	22-10-31	CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022	22-10-31	CI
Clarus Therapeutics Holdings, Inc. Announces Executive Changes	22-10-31	CI
Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc.	22-10-26	CI
Bidding Procedure Approved for Clarus Therapeutics Holdings, Inc.	22-09-22	CI
Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc.	22-09-07	CI
Health Care Up on Deal Activity -- Health Care Roundup	22-09-06	DJ
Motion for Asset Sale Filed by Clarus Therapeutics Holdings, Inc.	22-09-05	CI
Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.	22-09-05	CI
Clarus Therapeutics Holdings, Inc. Filed for Bankruptcy	22-09-05	CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from S&P TMI Index	22-09-02	CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from NASDAQ Composite Index	22-08-30	CI
Top Premarket Decliners	22-08-29	MT
North American Morning Briefing : Stock Futures -2-	22-08-23	DJ
Needham & Co Downgrades Clarus Therapeutics to Hold From Buy	22-08-22	MT
Maxim Downgrades Clarus Therapeutics Holdings to Hold From Buy	22-08-22	MT
Sector Update: Health Care Stocks Cross Friday Finish Line Slightly Higher	22-08-19	MT
Sector Update: Health Care Stocks a Rare Positive in Friday Trading	22-08-19	MT

Chart Clarus Therapeutics Holdings, Inc.

Duration

Period

Chart Clarus Therapeutics Holdings, Inc.

More charts

Company Profile

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company. The Company is engaged in the development of androgen-based medicines. The Company is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. It also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company's subsidiary is Clarus Therapeutics, Inc.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals